Nanjing Pharmaceutical Faces Valuation Shift Amid Declining Profitability and Financial Challenges

Nanjing Pharmaceutical Co., Ltd. has recently undergone an adjustment in its evaluation, reflecting notable shifts in its financial metrics. The company's valuation grade has been revised, indicating a transition from a previously assessed level to a more expensive classification. Key metrics such as the P/E ratio stand at 9, while the Price to Book Value is recorded at 0.93. The EV to EBIT and EV to EBITDA ratios are noted at 13.02 and 10.86, respectively, suggesting a complex valuation landscape. On the quality front, the company has experienced a revision in its score, moving from a good to an average classification. Sales growth over the past five years has been reported at 6.95%, with EBIT growth at 5.77%. The debt metrics reveal a Debt to EBITDA ratio of 5.77 and a Net Debt to Equity ratio of 1.40, highlighting the company's financial leverage. Despite a dividend yield of 3.49% and a Return on Equity of 10.58%, the company has faced challenges in maintaining profitability, as evidenced by a decline in profits over the past year. Overall, these adjustments reflect the evolving financial landscape for Nanjing Pharmaceutical Co., Ltd. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.